Manfred Kindler

Suggest Changes
Learn More
4552 Background: Everolimus (EVE, Afinitor) was approved for treatment of patients with metastatic renal cell cancer (mRCC) after failure of anti-VEGF therapy. Nevertheless, only limited prospective(More)
OBJECTIVE This study aimed to evaluate the impact of darbepoetin alfa (DA) on hemoglobin (Hb) levels and quality of life (QoL) in cancer patients with anemia in current daily practice following(More)